The State of Clinical Trials: China 2011
publication date: Nov 1, 2011
ChinaBio white paper on clinical trial activity in China.
The medical needs of China’s large and diverse population will continue to drive novel drug development
within China as the growth of its pharmaceutical industry quickly outpaces that of the rest of the world. This
growth has led to an increasing number of clinical trials performed in China, buy both domestic companies and western pharma. Additionally, as the SFDA continues to improve its regulations and the quality of clinical trials performed in China, domestically developed pharmaceuticals will have increasingly global applications, driving China to become
the #1 pharmaceutical market in the near future.
(PDF 1.5MB)